METHOD OF PREDICTING MASSIVE INTRAOPERATIVE BLOOD LOSS IN OPERATIONS ON ACCOUNT OF NON-ORGAN RETROPERITONEAL TUMOURS Russian patent published in 2013 - IPC A61B5/107 A61K31/715 A61P7/08 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, anesthesiology and intensive therapy, oncology, and can be applied in operations on account of non-organ retroperitoneal tumours. For this purpose prognostic criteria are determined on the basis of clinical and anamnestic parameters: Long stands for longitudinal dimension of tumour, in cm; Transv stands for transverse dimension of tumour, in cm; Rad stands for radical character of operation: 1 point means presence of radical intervention; 0 points means absence, palliative surgery, exploratory laparotomy; AddRes means carrying out additional resection of organs: 1 point means presence of organ resection; 0 points means operation only on tumour ablation; PorS stands for surgery on main vessels: 1 point stands for vascular plasty of arteries, resection of fragments of inferior vena cava, aorta; DifG stands for diffusion growth of tumour without capsulation: 1 point means presence; 0 points means absence. After that, coefficient of regression Z is calculated: Z=-0.581+0.038×Long+0.02×Transv+0.073×Rad+0.166×AddRes+0.133×PorS+0.102×DifG and substituted into formula: $$P_1=\frac{1}{1+e^{-\left(\mathrm{1,2}-\mathrm{4,18}\times Z\right)}}$$ where e is base of natural logarithm with value e=2.72. If P₁ constitutes from 0.87 to 0.26, massive intraoperative blood loss, requiring increased dose of colloids, but not more than 40 ml/kg/day in carrying out infusion therapy, is predicted.

EFFECT: method makes it possible to select optimal tactics of compensation of intravascular volume of colloids in operations in said category of patients due to more accurate calculation of blood loss volume.

1 ex